GlassScriptPhysician profile
Kraig Marvin Wangsnes
NPI 1659398394
$4,081.56
in general payments reported to CMS, 2019-2025
29 companies · $774 in 2025
The $774 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $203 · 2021: $218 · 2022: $678 · 2023: $714 · 2024: $575 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,425.61 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $900.58 | 2020-2025 | Avvigo Guidance System, Comet, General - Stents |
| Medtronic, INC. | $195.73 | 2022-2025 | Corevalve Evolut R |
| Medtronic Vascular, INC. | $175.22 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $156.89 | 2019-2022 | |
| Recor Medical INC | $148.34 | 2024 | Paradise Renal Denervation System |
| Pfizer INC. | $144.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $142.74 | 2019-2025 | |
| Cardiva Medical, INC. | $116.44 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.89 | 2019-2024 | Lifevest |
| Cardiovascular Systems INC. | $83.28 | 2019-2022 | |
| Angiodynamics, INC. | $50.72 | 2019 | |
| Terumo Medical Corporation | $49.44 | 2020-2025 | Metacross Otw, Glidewire, Angio-Seal |
| Sanofi-Aventis U.S. LLC | $49.23 | 2019 | |
| Philips North America LLC | $40.03 | 2025 | Ecc Solutions |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.76 | 2023-2025 | Eliquis, Camzyos |
| Cardinal Health 200 LLC | $31.36 | 2019 | |
| Shockwave Medical, INC | $30.88 | 2022 | |
| Inspire Medical Systems, INC. | $26.64 | 2024 | Inspire |
| Amgen INC. | $25.83 | 2019-2020 | |
| Inari Medical, INC. | $24.55 | 2021 | |
| Daiichi Sankyo INC. | $24.28 | 2023 | Injectafer |
| Cvrx, INC. | $20.65 | 2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.46 | 2022 | |
| Merck Sharp & Dohme LLC | $20.23 | 2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $16.50 | 2023 | Inpefa |
| Abiomed | $15.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $15.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kraig Wangsnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.